Tags · Compound
semaglutide
GLP-1 receptor agonist; the compound with the largest published human dataset in this class.
Related in this group: tirzepatide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues
80 topics · page 1 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on receptor…
|
+52 | 57 | 25k | just now |
|
Semaglutide formulation: what is in the licensed product besides the peptide
Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin semaglutide…
|
+29 | 35 | 4.4k | 1h |
|
Restarting after a long gap: what the labelling implies
Posting this under the heading it deserves: Restarting after a long gap: what the labelling implies Everything below is what sits behind that. I have read the maintained page on this and I still have a gap,…
|
+41 | 46 | 11k | 15h |
|
Molecular mass of semaglutide and why the figure differs between sources
Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+101 | 110 | 12k | 16h |
|
When a dose reduction is the correct response to a side effect
When a dose reduction is the correct response to a side effect — that is the question, and I have not found it answered plainly anywhere I have looked. I have read the maintained page on this and I still have…
|
+38 | 42 | 2.7k | 19h |
|
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…
|
+90 | 98 | 30k | 22h |
|
Tracking semaglutide's approved indications across jurisdictions, dated
Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
|
+15 | 19 | 2.8k | 1d |
|
What steady state means for the decision to escalate
What steady state means for the decision to escalate — that is the question, and I have not found it answered plainly anywhere I have looked. A question about steady state that I think has a definite answer,…
|
+31 | 35 | 2k | 1d |
|
Micro-titration: a disputed topic, argued properly — one year on
Posting this under the heading it deserves: Micro-titration: a disputed topic, argued properly — one year on Everything below is what sits behind that. Reading back through what has been written here about…
|
+63 | 68 | 35k | 1d |
|
Coming back to: Where the four-week escalation interval comes from, and what it is not
Posting this under the heading it deserves: Where the four-week escalation interval comes from, and what it is not Everything below is what sits behind that. Four-week escalation interval — I have the…
|
+44 | 48 | 11k | 1d |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile
Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. Semaglutide and gastric emptying,…
|
+115 | 122 | 2.6k | 1d |
|
Peak-to-trough ratio at steady state for a weekly agent — the long version
Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Peak-to-trough ratio,…
|
+57 | 61 | 708 | 1d |
|
Coming back to: Time to steady state after a dose increase
Time to steady state after a dose increase Writing it up because I had to work it out twice and would rather nobody else did. Working through the kinetics rather than the pharmacology, because I think the…
|
+104 | 110 | 16k | 2d |
|
Stepping down deliberately, and how to do it without losing progress — what changed since
Posting this under the heading it deserves: Stepping down deliberately, and how to do it without losing progress — what changed since Everything below is what sits behind that. Something changed and I would…
|
+94 | 99 | 29k | 2d |
|
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I would like to know what people here actually do about semaglutide…
|
+14 | 18 | 10k | 2d |
|
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…
|
+5 | 9 | 30k | 8d |
|
About the Receptor biology category
GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
+6 | 10 | 34k | 20d |
|
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I would like to know what…
|
+23 | 27 | 9.9k | 1mo |
|
When a dose reduction is the correct response to a side effect — a second dataset
When a dose reduction is the correct response to a side effect — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on dose…
|
+10 | 14 | 42k | 2mo |
|
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the…
|
+58 | 64 | 9.7k | 2mo |
|
Restarting after a long gap: what the labelling implies — the long version
Restarting after a long gap: what the labelling implies — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
|
+12 | 17 | 2.4k | 2mo |
|
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
|
2 | 7.5k | 2mo | |
|
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of clearance pathways is wrong? I…
|
+11 | 15 | 43k | 2mo |
|
The arithmetic of an intermediate dose between two label steps
On the subject in the title: The arithmetic of an intermediate dose between two label steps Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am…
|
2 | 136 | 2mo | |
|
Coming back to: Washout: how long is long enough, and for what purpose
Posting this under the heading it deserves: Washout: how long is long enough, and for what purpose Everything below is what sits behind that. A narrow question about Washout, deliberately narrow, because the…
|
+128 | 139 | 3k | 3mo |
|
Stepping down deliberately, and how to do it without losing progress
Stepping down deliberately, and how to do it without losing progress — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how…
|
+98 | 102 | 26k | 3mo |
|
GLP-1 receptor distribution: central and peripheral — one year on
GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…
|
+7 | 11 | 43k | 3mo |
|
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the…
|
+14 | 18 | 15k | 3mo |
|
Half-life, steady state, and accumulation worked through — a second dataset
Half-life, steady state, and accumulation worked through — a second dataset — setting out what I have, and where I think it stops being reliable. Working through the kinetics rather than the pharmacology,…
|
+110 | 126 | 14k | 4mo |
|
Why semaglutide solutions can look faintly opalescent and when that matters
The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. A follow-up question about…
|
+73 | 79 | 2k | 4mo |